{
  "symbol": "BEAM",
  "company": "Beam Therapeutics Inc.",
  "generated_at": "2026-06-24T07:36:45.583Z",
  "event_count": 2,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-09T02:31:54.576Z",
      "stage": "scout",
      "outcome": "failed",
      "reason": null,
      "trigger": "[8k_recent] 1 recent 8-K(s) in last 7 days, latest filed 2026-06-08",
      "source": "hunter"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-06T03:40:13.256Z",
      "summary": "Beam Therapeutics is a pre-commercial base-editing biotech with two high-value catalysts approaching: (1) a potential sickle cell BLA filing by end-2026 and (2) a pivotal expansion cohort for BEAM-302 in alpha-1 antitrypsin deficiency (AATD) beginning H2 2026 after strong Phase 1/2 dose-selection data presented at ATS May 2026. The stock has surged ~23% YTD on the back of positive clinical updates, reaching $36.44 intraday high before today's -10.5% pullback to $29.40. Vanguard disclosed a ~5% stake in April 2026 and multiple insider open-market purchases clustered around late January (post-Q4 results) and March-April suggest smart-money conviction at higher levels than current price. The company has ~3 years of cash runway, elevated IV (75-90%) creating income structure opportunity, and the analyst consensus target of $51 implies 74% upside from here. SEC rate-limiting prevented direct reading of 10-K/10-Q text, but cross-referencing news + fundamentals yields a coherent picture: pre-commercial gene editor with near-term regulatory catalyst — fully priced on pure hope OR meaningfully undervalued given where insiders are buying? The answer determines whether this is 'promising' or 'range_bound_or_income'.",
      "verdict": "no_anomaly",
      "confidence": 3,
      "tool_calls": 31,
      "walltime_min": 10,
      "debug_path": "dossiers/2026-06-06-BEAM.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "BEAM",
    "call": "BUY",
    "confidence": 5,
    "score": 7,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_up": "+2 (61.3%)",
      "rsi_neutral": "0 (56.6)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (3d ago)",
      "from_high": "0 (-6.6%)"
    },
    "summary": "BUY (score +7) · 12-1 mom 61.3% · RSI 56.6 · above_both · -6.6% from high",
    "last_close": 33.2,
    "one_month_ago_close": 27.67,
    "twelve_month_ago_close": 17.15,
    "twelve_one_momentum_pct": 61.34,
    "rsi_14": 56.6,
    "ma_stack": "above_both",
    "from_period_high_pct": -6.56,
    "period_high": 35.53,
    "price_targets": {
      "bear": 24.87,
      "fair": 38.24,
      "bull": 80,
      "bear_return_pct": -25.1,
      "fair_return_pct": 15.2,
      "bull_return_pct": 141,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 26,
        "target_mean": 51.06667,
        "target_high": 80,
        "analyst_count": 15
      }
    },
    "generated_at": "2026-06-24T07:36:45.579Z"
  }
}